Meeting
2022 ASCO Annual Meeting
Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.
Authors
Neha Mehta-Shah
Memorial Sloan Kettering Cancer Center, New York, NY
Neha Mehta-Shah , Susan Michelle Geyer , Stefan K. Barta , Jennifer Effie Amengual , Travis Dockter , Chadwick Wright , Shira Dinner , Eric D. Hsi , Nancy L. Bartlett , Steven M. Horwitz , Brad S. Kahl , Jonathan W. Friedberg , John Paul Leonard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04803201
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7593)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7593
Abstract #
TPS7593
Poster Bd #
238a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL).
First Author: Kunihiro Tsukasaki
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.
First Author: Andrea Necchi
Poster
2022 ASCO Annual Meeting
Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors.
First Author: Sébastien Perreault
Poster
2021 ASCO Annual Meeting
Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
First Author: Juergen Wolf